Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned an average recommendation of “Hold” from the eighteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $156.8824.

Several research analysts have commented on the company. Canaccord Genuity Group raised their price objective on Illumina from $140.00 to $190.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research report on Thursday, May 14th. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and increased their target price for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Guggenheim raised their target price on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Evercore reiterated an “outperform” rating on shares of Illumina in a report on Monday, July 6th.

Illumina Stock Up 1.9%

Shares of NASDAQ:ILMN opened at $192.98 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a 1 year low of $88.00 and a 1 year high of $199.14. The stock has a market capitalization of $29.20 billion, a P/E ratio of 35.09, a PEG ratio of 2.80 and a beta of 1.47. The stock has a 50-day simple moving average of $173.22 and a 200-day simple moving average of $146.03.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $0.97 EPS. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts forecast that Illumina will post 5.22 earnings per share for the current year.

Insider Activity

In other news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total transaction of $110,700.00. Following the transaction, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock worth $155,710,908 over the last three months. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several hedge funds and other institutional investors have recently modified their holdings of ILMN. HighPoint Advisor Group LLC raised its holdings in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares during the last quarter. Elevation Wealth Partners LLC increased its position in Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares during the period. Meeder Advisory Services Inc. raised its stake in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares in the last quarter. Toronto Dominion Bank grew its stake in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares in the last quarter. Finally, Panagora Asset Management Inc. increased its holdings in shares of Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.